BioNTech pays $20M upfront for two monoclonal antibodies from China's WuXi Biologics
BioNTech is paying out $20 million upfront to another Chinese partner in exchange for the rights to develop two preclinical monoclonal antibodies, this time with CRDMO WuXi Biologics.
The deal also includes research, development, regulatory and commercial milestone payments, plus tiered royalties for the Shanghai-based company, which will use its antibody discovery technology platforms to discover the antibodies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.